DK1056759T3 - 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol-derivater - Google Patents

2-(Purin-9-yl)-tetrahydrofuran-3,4-diol-derivater

Info

Publication number: DK1056759T3
Authority: DK; Denmark
Prior art keywords: purin; tetrahydrofuran; diol derivatives; diol; derivatives
Prior art date: 1998-02-14

Application number

DK99906229T

Other languages

English (en)

Inventor

Caroline Mary Cook

Brian Cox

Richard Peter C Cousins

Hazel Joan Dyke

Joanna V Geden

Stephen Swanson

David Bays

Chuen Chan

Frank Ellis

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-14

Filing date

1999-02-12

Publication date

2003-01-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1056759(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-02-14 Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en

1998-06-23 Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en

1999-02-12 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2003-01-06 Application granted granted Critical

2003-01-06 Publication of DK1056759T3 publication Critical patent/DK1056759T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK99906229T 1998-02-14 1999-02-12 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol-derivater DK1056759T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9803169.3A GB9803169D0 (en)	1998-02-14	1998-02-14	Chemical compounds
GBGB9813533.8A GB9813533D0 (en)	1998-06-23	1998-06-23	Chemical compounds
PCT/EP1999/000915 WO1999041267A1 (en)	1998-02-14	1999-02-12	2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives

Publications (1)

Publication Number	Publication Date
DK1056759T3 true DK1056759T3 (da)	2003-01-06

Family

ID=26313119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99906229T DK1056759T3 (da)	1998-02-14	1999-02-12	2-(Purin-9-yl)-tetrahydrofuran-3,4-diol-derivater

Country Status (32)

Country	Link
US (1)	US6610665B1 (da)
EP (1)	EP1056759B1 (da)
JP (1)	JP2002503669A (da)
KR (1)	KR20010082512A (da)
AP (1)	AP2000001881A0 (da)
AR (1)	AR017457A1 (da)
AT (1)	ATE223429T1 (da)
AU (1)	AU757156B2 (da)
BR (1)	BR9907886A (da)
CA (1)	CA2319009A1 (da)
CO (1)	CO4990969A1 (da)
DE (1)	DE69902758T2 (da)
DK (1)	DK1056759T3 (da)
EA (1)	EA200000759A1 (da)
EE (1)	EE200000358A (da)
ES (1)	ES2183516T3 (da)
HK (1)	HK1032062A1 (da)
HR (1)	HRP20000538A2 (da)
HU (1)	HUP0100702A3 (da)
IL (1)	IL137402A0 (da)
IS (1)	IS5576A (da)
MA (1)	MA27121A1 (da)
NO (1)	NO20004045L (da)
NZ (1)	NZ505812A (da)
PE (1)	PE20000270A1 (da)
PL (1)	PL342396A1 (da)
PT (1)	PT1056759E (da)
SK (1)	SK12002000A3 (da)
SV (1)	SV1999000016A (da)
TR (1)	TR200002355T2 (da)
WO (1)	WO1999041267A1 (da)
YU (1)	YU50800A (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6514949B1 (en)	1994-07-11	2003-02-04	University Of Virginia Patent Foundation	Method compositions for treating the inflammatory response
YU44900A (sh) *	1998-01-31	2003-01-31	Glaxo Group Limited	Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) *	1998-02-14	2000-05-20	Glaxo Group Ltd	Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
CN1313861A (zh)	1998-06-23	2001-09-19	葛兰素集团有限公司	2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物
GB9813554D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813565D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
US7378400B2 (en)	1999-02-01	2008-05-27	University Of Virginia Patent Foundation	Method to reduce an inflammatory response from arthritis
US7427606B2 (en)	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en)	1999-02-01	2001-05-15	University Of Virginia Patent Foundation	Methods and compositions for treating inflammatory response
GB9930075D0 (en) *	1999-12-20	2000-02-09	Glaxo Group Ltd	Medicaments
US7638496B2 (en)	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
GB0115178D0 (en) *	2001-06-20	2001-08-15	Glaxo Group Ltd	Compounds
WO2003029264A2 (en)	2001-10-01	2003-04-10	University Of Virginia Patent Foundation	2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
US6930093B2 (en) *	2003-07-10	2005-08-16	Valeant Research & Development	Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
TWI346109B (en)	2004-04-30	2011-08-01	Otsuka Pharma Co Ltd	4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
AR049384A1 (es)	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
EP2266994B1 (en)	2004-08-02	2013-04-03	University Of Virginia Patent Foundation	2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en)	2004-08-02	2006-03-02	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having a2a agonist activity
US7576069B2 (en)	2004-08-02	2009-08-18	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
KR20130020850A (ko)	2005-10-21	2013-02-28	노파르티스 아게	Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
CA2664378A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as pi3k lipid kinase inhibitors
KR20090075714A (ko)	2006-10-30	2009-07-08	노파르티스 아게	소염제로서의 헤테로시클릭 화합물
US8431578B2 (en)	2008-01-11	2013-04-30	Novartis Ag	Organic compounds
PL2391366T3 (pl)	2009-01-29	2013-04-30	Novartis Ag	Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es)	2009-08-12	2012-02-29	Novartis Ag	Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
US9085560B2 (en)	2009-08-17	2015-07-21	Intellikine, Inc.	Heterocyclic compounds and uses thereof
CA2771432A1 (en)	2009-08-20	2011-02-24	Novartis Ag	Heterocyclic oxime compounds
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
JP5959541B2 (ja)	2011-02-25	2016-08-02	ノバルティスアーゲー	Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
AU2012310168B2 (en)	2011-09-15	2015-07-16	Novartis Ag	6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
US20130209543A1 (en)	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
RU2660354C2 (ru)	2012-04-03	2018-07-05	Новартис Аг	Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
CN105246482A (zh)	2013-03-15	2016-01-13	因特利凯有限责任公司	激酶抑制剂的组合及其用途
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
RU2695230C2 (ru)	2014-07-31	2019-07-22	Новартис Аг	Сочетанная терапия
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9414193D0 (en)	1994-07-14	1994-08-31	Glaxo Group Ltd	Compounds
TW528755B (en) *	1996-12-24	2003-04-21	Glaxo Group Ltd	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
PE20000270A1 (es) *	1998-02-14	2000-05-20	Glaxo Group Ltd	Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
CN1313861A (zh) *	1998-06-23	2001-09-19	葛兰素集团有限公司	2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物

1999
- 1999-02-11 PE PE1999000123A patent/PE20000270A1/es not_active Application Discontinuation
- 1999-02-11 AR ARP990100570A patent/AR017457A1/es active IP Right Grant
- 1999-02-11 CO CO99008188A patent/CO4990969A1/es unknown
- 1999-02-12 KR KR1020007008866A patent/KR20010082512A/ko not_active Application Discontinuation
- 1999-02-12 EP EP99906229A patent/EP1056759B1/en not_active Expired - Lifetime
- 1999-02-12 PT PT99906229T patent/PT1056759E/pt unknown
- 1999-02-12 AP APAP/P/2000/001881A patent/AP2000001881A0/en unknown
- 1999-02-12 DK DK99906229T patent/DK1056759T3/da active
- 1999-02-12 EE EEP200000358A patent/EE200000358A/xx unknown
- 1999-02-12 EA EA200000759A patent/EA200000759A1/ru unknown
- 1999-02-12 WO PCT/EP1999/000915 patent/WO1999041267A1/en not_active Application Discontinuation
- 1999-02-12 TR TR2000/02355T patent/TR200002355T2/xx unknown
- 1999-02-12 NZ NZ505812A patent/NZ505812A/en unknown
- 1999-02-12 DE DE69902758T patent/DE69902758T2/de not_active Expired - Fee Related
- 1999-02-12 ES ES99906229T patent/ES2183516T3/es not_active Expired - Lifetime
- 1999-02-12 SK SK1200-2000A patent/SK12002000A3/sk unknown
- 1999-02-12 YU YU50800A patent/YU50800A/sh unknown
- 1999-02-12 AU AU26235/99A patent/AU757156B2/en not_active Ceased
- 1999-02-12 JP JP2000531459A patent/JP2002503669A/ja active Pending
- 1999-02-12 SV SV1999000016A patent/SV1999000016A/es not_active Application Discontinuation
- 1999-02-12 AT AT99906229T patent/ATE223429T1/de not_active IP Right Cessation
- 1999-02-12 IL IL13740299A patent/IL137402A0/xx unknown
- 1999-02-12 HU HU0100702A patent/HUP0100702A3/hu unknown
- 1999-02-12 BR BR9907886-4A patent/BR9907886A/pt not_active IP Right Cessation
- 1999-02-12 PL PL99342396A patent/PL342396A1/xx unknown
- 1999-02-12 US US09/622,313 patent/US6610665B1/en not_active Expired - Fee Related
- 1999-02-12 MA MA25462A patent/MA27121A1/fr unknown
- 1999-02-12 CA CA002319009A patent/CA2319009A1/en not_active Abandoned
2000
- 2000-07-25 IS IS5576A patent/IS5576A/is unknown
- 2000-08-11 HR HR20000538A patent/HRP20000538A2/hr not_active Application Discontinuation
- 2000-08-11 NO NO20004045A patent/NO20004045L/no unknown
2001
- 2001-04-10 HK HK01102563A patent/HK1032062A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
IS5576A (is)	2000-07-25
AU2623599A (en)	1999-08-30
BR9907886A (pt)	2000-10-17
SV1999000016A (es)	1999-10-27
DE69902758T2 (de)	2003-05-15
EP1056759B1 (en)	2002-09-04
MA27121A1 (fr)	2005-01-03
WO1999041267A1 (en)	1999-08-19
PT1056759E (pt)	2003-01-31
JP2002503669A (ja)	2002-02-05
SK12002000A3 (sk)	2001-07-10
NO20004045D0 (no)	2000-08-11
NO20004045L (no)	2000-08-11
KR20010082512A (ko)	2001-08-30
AR017457A1 (es)	2001-09-05
US6610665B1 (en)	2003-08-26
CA2319009A1 (en)	1999-08-19
PL342396A1 (en)	2001-06-04
HUP0100702A3 (en)	2003-01-28
HK1032062A1 (en)	2001-07-06
AU757156B2 (en)	2003-02-06
IL137402A0 (en)	2001-07-24
DE69902758D1 (de)	2002-10-10
CO4990969A1 (es)	2000-12-26
HUP0100702A2 (hu)	2002-01-28
ATE223429T1 (de)	2002-09-15
EE200000358A (et)	2001-10-15
PE20000270A1 (es)	2000-05-20
ES2183516T3 (es)	2003-03-16
AP2000001881A0 (en)	2000-09-30
EP1056759A1 (en)	2000-12-06
NZ505812A (en)	2002-03-01
EA200000759A1 (ru)	2001-04-23
YU50800A (sh)	2003-04-30
HRP20000538A2 (en)	2000-12-31
TR200002355T2 (tr)	2000-11-21

Publication	Publication Date	Title
DE69903708D1 (de)	2002-12-05	2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate
IS5779A (is)	2000-12-19	2-(púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður
DK1056759T3 (da)	2003-01-06	2-(Purin-9-yl)-tetrahydrofuran-3,4-diol-derivater
IS5774A (is)	2000-12-15	2-(púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður
DK0948509T3 (da)	2003-02-24	2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater
SI1056759T1 (en)	2003-04-30	2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives
ZA99689B (en)	2000-07-28	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
ZA991154B (en)	2000-08-14	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
ZA9711535B (en)	1999-06-22	2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives